dc.contributor.author | Örmeci, Aslı | |
dc.contributor.author | Aydın, Yücel | |
dc.contributor.author | Şumnu, Abdullah | |
dc.contributor.author | Baran, Bülent | |
dc.contributor.author | Mutluay Soyer, Özlem | |
dc.contributor.author | Pınarbaşı, Binnur | |
dc.contributor.author | Göktürk, Suut | |
dc.contributor.author | Güllüoǧlu, Mine | |
dc.contributor.author | Önel, Derya | |
dc.contributor.author | Badur, Selim | |
dc.contributor.author | Akyüz, Filiz | |
dc.contributor.author | Karaca, Çetin | |
dc.contributor.author | Demir, Kadir | |
dc.contributor.author | Beşışık, Fatih | |
dc.contributor.author | Kaymakoğlu, Sabahattin | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:56:41Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T19:56:41Z | |
dc.date.issued | 2016 | en_US |
dc.identifier.citation | Örmeci, A., Aydın, Y., Şumnu, A., Baran, B., Mutluay Soyer, Ö., Pınarbaşı, B. ... Kaymakoğlu, S. (2016). Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels. 52, 68-73. https://dx.doi.org/10.1016/j.ijid.2016.09.007 | en_US |
dc.identifier.issn | 1201-9712 | |
dc.identifier.issn | 1878-3511 | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.ijid.2016.09.007 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/2789 | |
dc.description | WOS: 000389516600014 | en_US |
dc.description | PubMed ID: 27619844 | en_US |
dc.description.abstract | Objectives: Serum alanine aminotransferase (ALT) is a controversial marker for disease monitoring in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. The aim of this study was to determine the fibrosis stage and histological activity index (HAI) in HBeAg-negative CHB patients with persistently normal ALT (PNALT) and high serum HBV DNA (>= 2000 IU/ml) and to investigate clinical risk factors for the requirement of treatment through the examination of liver biopsy specimens. Methods: HBeAg-negative CHB patients with PNALT (<= 40 IU/l) and high serum HBV DNA (>= 2000 IU/ml) were included. HBV fibrosis stage and HAI were scored according to the Ishak system. Multivariate logistic regression analysis was used to estimate the independent risk factors for fibrosis stage >= 2 and/or HAI >= 6. Receiver operating characteristic curve analysis was used to determine an optimal age cut-off for liver biopsy. Results: A total 120 patients were enrolled. These patients had a mean HBV DNA level of 123 680 +/- 494 500 IU/ml; the HBV DNA load was 2000-20 000 IU/ml in 68 patients (56.6%) and >= 20 000 IU/ml in 52 (43.4%). Eighteen patients (15%) had moderate-to-severe histological activity (HAI >= 6). Forty-three patients (35.9%) had a fibrosis stage >= 2. Forty-eight patients (40%) had a fibrosis stage >= 2 and/or HAI >= 6. On multivariate logistic regression analysis, independent variables associated with fibrosis stage >= 2 and/or HAI >= 6 included age and HBV DNA viral load. Patients with HBV DNA 2000-20 000 IU/ml were more likely to require treatment compared to those with a viral load >= 20 000 IU/ml. The optimal age cut-off to predict fibrosis stage >= 2 and/or HAI >= 6 was 46 years. Conclusions: Significant liver damage was detected in 40% of CHB patients with PNALT and high HBV DNA upon biopsy. Age and HBV DNA viral load were independent predictors of significant liver damage. A biopsy to determine the degree of liver damage is advisable for CHB patients older than 46 years. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Chronic Hepatitis B | en_US |
dc.subject | HBeAg-Negative | en_US |
dc.subject | Persistently Normal ALT | en_US |
dc.title | Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels | en_US |
dc.type | article | en_US |
dc.relation.ispartof | International Journal of Infectious Diseases | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 52 | en_US |
dc.identifier.startpage | 68 | en_US |
dc.identifier.endpage | 73 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.ijid.2016.09.007 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.scopusquality | Q1 | en_US |